Page 239 - 2021_10-Haematologica-web

Letters to the Editor
Memphis, TN, USA; 8Department of Leukemia, The University of Texas MD Anderson Cancer Center; Houston, TX, USA; 9Department of Pediatric Hematology/Immunology, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France; 10Université de Cote d'Azur, INSERM, C3M; Nice, France and 10Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA
*LMN and JPL contributed equally as co-first authors #PSR and SKT contributed equally as co-senior authors Correspondence:
SARAH K. TASIAN - tasians@chop.edu doi:10.3324/haematol.2021.278697
Received: March 3, 2021. Accepted: June 16, 2021. Pre-published: July 1, 2021.
Disclosures: SKT receives research funding from Incyte Corporation for Ph-like ALL studies; II has received honoraria from Amgen for unrelated studies; CGM receives/d research funding from Abbvie, Loxo Oncology, and Pfizer for unrelated studies, has received speaking and travel fees from Illumina and Amgen, and holds stock in Amgen; NJ receives/d research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics, and Kite and has received consulting fees from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics, ADC Therapeutics, Cellectis, BMS for unrelated studies; MK receives/d research funding or consulting fees from Hoffman/La-Roche, Stemline Therapeutics, Forty-Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, Astra Zeneca, Rafael Pharmaceuticals, Sanofi, Janssen, and Genentech for unrelated studies; SKT receives/d research funding from Gilead Sciences and is a scientific advisory board member for Aleta Biotherapeutics and Kura Oncology for unrelated studies. The remaining authors declare
no conflicts of interest.
Contributions: LMN analyzed and interpreted data and contributed to manuscript writing; JPL and DHA performed preclinical experiments and analyzed data; EL and AC-E performed clinical specimen assays, analyzed and interpreted data; MP provided clinical patient care and contributed to manuscript writing; II, CGM, NJ, and MK provided primary patient or PDX specimens and scientific input; HC and AB provided critical scientific advice and interpreted clinical genetic testing data; PSR and SKT conceived and directed the study, provided clinical patient care, analyzed and interpreted data, and wrote and/or edited the manuscript. All authors reviewed and approved the manuscript prior to submission.
Acknowledgments: we gratefully acknowledge the Center for Biological Resources (‘CRB-cancer’) of the Robert Debré Hospital (BB-0033-00076; EL, AC-E, and HC), Drs I-Ming Chen and Richard Harvey at the University of New Mexico for performing Ph-like ALL low density microarray expression analysis of primary clinical and patient-derived xenograft (PDX) model ALL specimens, Ms Elizabeth Wagner at Nationwide Children’s Hospital for clinical annotation of COG ALL specimens, Dr Marilyn Li at CHOP for per- forming genetic characterisation of PDX models, and Dr Matthew Stubbs at Incyte Corporation for provision of ruxolitinib rodent chow for preclinical animal studies. We also kindly thank Dr Vandana Batra at the Children’s Hospital of Philadelphia, Dr Jing Chen at Hackensack University Medical Center, and Dr Michael Loschi at CHU de Nice for assisting in clinical patient care. This study is dedicated in honor
of Miss Emily Herrera and Miss Ava Daisy Phillips.
Funding: these studies were supported by United States National Institutes of Health (NIH)/National Institute of Child Health and
Human Development award T32HD043021 (LMN), NIH/National Cancer Institute (NCI) award T32CA009615 (LMN), 1U01CA232486 (SKT), U01CA243072 (SKT), the ERA-NET TRANSCAN/Foundation ARC (EL, AC-E, HC), Department of Defense Translational Team Science award CA180683P1, the V Foundation for Cancer Research (SKT), the Sohn Monaco Foundation (PSR), and the PHRC program from the French Institut National du Cancer (PSR). Children’s Oncology Group (COG) specimen banking was supported by NCI U24CA114766 and U24CA196173. Childhood IGH-EPOR ALL PDX modeling was also supported
by a Lady Tata Memorial Trust Award (II), St Jude Children’s Research Hospital Hematological Malignancies Program Garwood Fellowship (II), Leukemia and Lymphoma Society Specialized Center of Research (CGM), Stand up to Cancer Innovative Research Grant (CGM), St Baldrick’s Foundation Scholar award (CGM), NCI Outstanding Investigator Award R35CA197695 (CGM),
and NIH Cancer Center Support Grant P30 CA21765 (CGM).
References
1. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome–like acute lymphoblastic leukemia. Blood. 2017;130(19):2064-2072.
2. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
3. Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020;4(1):218-228.
4. Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosomelLike acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394-401.
5. Iacobucci I, Li Y, Roberts KG, et al. Truncating erythropoietin recep- tor rearrangements in acute lymphoblastic leukemia. Cancer Cell. 2016;29(2):186-200.
6. Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph- like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention. Blood. 2013;122(21):826-826.
7. Tasian SK, Assad A, Hunter DS, Du Y, Loh ML. A Phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chro- mosome-like acute lymphoblastic leukemia (INCB18424- 269/AALL1521): dose-finding results from the Part 1 Safety Phase. Blood. 2018;132(Suppl 1):S555.
8. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14(12):2205-2222.
9. Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177- 187.
10.Tasian SK, Hurtz C, Wertheim GB, et al. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017;31(4):981-984.
11.Hurtz C, Wertheim GB, Loftus JP, et al. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest. 2020;130(7):3637-3653.
12. Jain N, Jabbour EJ, McKay PZ, et al. Ruxolitinib or dasatinib in com- bination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial. Blood. 2017;130(Suppl 1):S1322.
13. Russell LJ, De Castro DG, Griffiths M, et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia. 2009;23(3):614-617.
14. Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorti- coid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810.
15. Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618-e627.
haematologica | 2021; 106(10)
2767